Allena Pharmaceuticals, Inc. announced that its Board of Directors appointed Richard Katz to serve as the Company’s Principal Financial Officer and Principal Accounting Officer. Katz succeeds Edward Wholihan as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer of the Company, whose planned departure was announced by the Company in November 2020, effective as of January 29, 2021. Prior to his appointment to the Company, Katz served as Chief Financial Officer at Liquidia Technologies, Inc., from May 2019 to August 2020. Prior to Liquidia, he served as Vice President and Chief Financial Officer of Argos Therapeutics, Inc., from July 2016 until November 2018. Prior to joining Argos Therapeutics, Katz served as Chief Financial Officer for Viamet Pharmaceuticals, Inc., from February 2012 to May 2016. Dr. Katz also served as Chief Financial Officer at Icagen, Inc., from April 2001 to November 2011, where he was instrumental in the company’s initial public offering and subsequent financings, the formation of several strategic collaborations, and the company’s sale to Pfizer. Katz began his career as a vice president in the healthcare investment banking group at Goldman Sachs & Company, where he executed a broad range of transactions, including equity and debt financings, mergers and acquisitions and corporate restructurings.